scholarly journals FORMULATION AND EVALUATION OF IMMEDIATE RELEASE TABLETS OF METFORMIN HYDROCHLORIDE ON LABORATORY SCALE

2011 ◽  
Vol 1 (2) ◽  
Author(s):  
Manoj S. Charde ◽  
S. Jayani ◽  
D. Pandey ◽  
R. D. Chakole
Keyword(s):  
Immediate Release ◽  
Laboratory Scale ◽  
Metformin Hydrochloride

scholarly journals COMPARATIVE IN VITRO DISSOLUTION STUDY ON METFORMIN MARKET PRODUCTS USING DIFFERENT DISSOLUTION APPARATUSES

2019 ◽  
pp. 65-72
Author(s):  
HANAN M. HASHEM ◽  
AYA R. ABDOU ◽  
NADIA M. MURSI ◽  
LAILA H. EMARA
Keyword(s):  
Reference Product ◽  
Immediate Release ◽  
In Vitro Dissolution ◽  
Metformin Hydrochloride ◽  
Innovator Product ◽  
Similarity Factor ◽  
Generic Products ◽  
Dissolution Efficiency ◽  
Usp Apparatus

Objective: This study was proposed to evaluate and compare the in vitro dissolution profiles of six Metformin Hydrochloride (MH) market products. Methods: Different dissolution apparatuses (USP apparatus II, IV and beaker method) were used to evaluate the dissolution profiles (in phosphate buffer, pH 6.8) of two immediate release (IR) generic products of Metformin Hydrochloride (MH): Cidophage® 1000 mg (G1, Egyptian market) and Metformin arrow® 1000 mg (G2, French market) with respect to the reference products named Glucophage® 850 mg (R1, Egyptian market and R2, French market). In addition to a generic controlled-release (CR) product; Cidophage Retard® 850 mg (G3) versus the reference product; Glucophage XR® 1000 mg (R3) (both from Egyptian market). Dissolution efficiency (D. E.) and the similarity factor (f2) were calculated. Weight uniformity, hardness, tablet dimensions and MH content were measured. Results: Results of the three apparatuses showed that MH IR products studied (reference and generics) did not meet the 75% USP 30 specifications for MH dissolved at 30 min. For MH CR products, Glucophage XR® did not fulfill the USP release criteria, while Cidophage Retard® did. USP apparatus IV revealed the highest sensitivity and discriminative capability. Conclusion: Generally, MH IR generics (G1 and G2) might be interchangeable with the innovator product (Glucophage®). However, Cidophage Retard® might not be interchangeable with Glucophage XR®.

Influence of dissolution media pH and USP1 basket speed on erosion and disintegration characteristics of immediate release metformin hydrochloride tablets

2014 ◽  
Vol 20 (5) ◽  
pp. 540-545 ◽  
Author(s):  
Divyakant Desai ◽  
Benjamin Wong ◽  
Yande Huang ◽  
Dan Tang ◽  
Jeffrey Hemenway ◽  
...  
Keyword(s):  
Immediate Release ◽  
Metformin Hydrochloride

scholarly journals Formulation and Evaluation of Immediate Release Tablet Dosage Form of Linagliptin and Metformin Hydrochloride

2021 ◽  
Vol 11 (3-S) ◽  
pp. 61-64
Author(s):  
Rakesh Kumar Jat ◽  
Sukanta Chatterjee
Keyword(s):  
Dosage Form ◽  
Drug Product ◽  
Scale Up ◽  
Immediate Release ◽  
Fixed Dose ◽  
Metformin Hydrochloride ◽  
Solid Dosage ◽  
Model Drug ◽  
The Individual ◽  
Tablet Dosage

The aim of the current study work was to formulate and assess a fixed dose mixture tablet of instant release oral solid dosage form comprising two anti-diabetic drugs (linagliptin and metformin hydrochloride) for managing of diabetes mellitus type 2.The innovator drug product (Jentadueto Tablet) was evaluated for the various evaluation parameters, which have been taken into consideration during the drug product development. Pre-formulation evaluation was accomplished to safeguard better parameters of formulated drug product. On the result of pre-formulation evaluation and innovator drug product characterization, the model drug product was recognized in various steps. The established formulation was augmented for different excipients. The instant release film covered tablet of linagliptin and metformin HCl was expressed and augmented at laboratory scale. The individual steps (procedures) were improved for the same and the scale-up contemplation have been engaged into account certify the product performance at pilot plant-up to commercial scale-up. Keywords: anti-diabetic, linagliptin, metformin

scholarly journals DEVELOPMENT AND EVALUATION OF BILAYER TABLETS FOR IMMEDIATE AND CONTROLLED RELEASE OF METFORMIN HYDROCHLORIDE

2017 ◽  
pp. 173-179
Author(s):  
Rablee Saikia ◽  
Bhanu Pratap Sahu
Keyword(s):  
Controlled Release ◽  
Sustained Release ◽  
Effective Treatment ◽  
In Vitro Release ◽  
Immediate Release ◽  
Metformin Hydrochloride ◽  
Wet Granulation ◽  
Time Interval ◽  
Weight Variation

Objective: The purpose of this study was to develop and evaluate bi-layer tablets for the immediate and controlled release of Metformin Hydrochloride for effective treatment of type 2 Diabetes mellitus.Methods: The immediate release layer was prepared by using super disintegrants like cross carmellose sodium, sodium starch glycolate and sustained release layer was prepared by using hydrophilic polymer like HPMC K 100 and PVP. Various proportions of super disintegrants and polymer were used to select the best formulation composition. Bilayer tablet of metformin was prepared by wet granulation method and was evaluated for physical characteristics like hardness, weight variation, and friability. In vitro release of drug was performed in USP type II dissolution test apparatus using phosphate buffer (pH 6.8) as dissolution media and dissolution was continued for 9 h for the sustained release layer. For immediate release layer, readings were recorded in each 10 min time interval for the first 1h.Results: From the obtained result it was found that all the formulations were within the limit of the standard. The hardness was found to be in the ranges from 5.1 to 5.5 kg/cm2, weight variation was in the range 0.53% to 0.83%, friability of all the formulations was within the range (<1%)and percentage of drug content was more than 97%. The drug release of the tablet was in the range of 85%-91% in 9 h.Conclusion: From the result obtained, it is found that the formulation F6 satisfies all the criteria as sustained release tablet for the effective treatment of type 2Diabetes mellitus.  

scholarly journals Preparation and Evaluation of Natural Gum-Based Immediate Release Metformin Hydrochloride Tablet

2018 ◽  
Vol 21 (2) ◽  
pp. 101-108
Author(s):  
Sreebash Chandra Bhowmik ◽  
Marzia Alam ◽  
Md Saiful Islam Pathan
Keyword(s):  
Immediate Release ◽  
Angle Of Repose ◽  
Metformin Hydrochloride ◽  
Wet Granulation ◽  
Class Iii ◽  
Aegle Marmelos ◽  
Disintegration Time ◽  
Weight Variation ◽  
Natural Gum

Metformin hydrochloride is a first line BCS class III oral anti-diabetic drug used for the treatment of type 2 diabetes. The main goal of this study was to formulate, prepare and evaluate natural gum-based immediate release metformin hydrochloride tablet. Seven different formulations of compressed tablets were prepared following wet granulation process using different concentrations (10, 20, 30, 50, 60, 70, 80 and 90 mg) of Aegle marmelos gum as a binder. Aegle marmelos gum is a biodegradable natural gum which is economic, easily available and found useful as tablet binder for both conventional and novel dosage forms. Other excipients used in the formulation were microcrystalline cellulose (MCC), croscarmellose sodium (CCS), maize starch, colloidal silicon dioxide (CSD), sodium starch glycolate (SSG), magnesium stearate etc. In the present study, the compressed tablets were evaluated for weight variation, thickness, hardness, friability, disintegration time and dissolution. In vitro drug release study was carried out in phosphate buffer (pH 6.8) at 37 ± 0.5oC with 50 rpm using USP Dissolution Apparatus 2-Paddle method. The flowability of granules for all the batches was optimum which reflected in the bulk density and angle of repose. It can be concluded from this study that combination of Aegle marmelos as a binder with other excipients can be prospectively used in the preparation of metformin hydrochloride immediate release (IR) tablet.Bangladesh Pharmaceutical Journal 21(2): 101-108, 2018

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride

2021 ◽  
Author(s):  
Melissa Metry ◽  
Yan Shu ◽  
Bertil Abrahamsson ◽  
Rodrigo Cristofoletti ◽  
Jennifer B. Dressman ◽  
...  
Keyword(s):  
Immediate Release ◽  
Dosage Forms ◽  
Oral Dosage ◽  
Metformin Hydrochloride ◽  
Solid Oral Dosage Forms ◽  
Oral Dosage Forms

Formulation and Release Characteristic of a Bilayer Matrix Tablet Containing Glimepride Immediate Release Component and Metformin Hydrochloride as Sustained Release Component

2010 ◽  
Vol 3 (1) ◽  
pp. 851-859
Author(s):  
Y Madhusudan Rao ◽  
Sunil Reddy ◽  
Panakanti Pavan Kumar ◽  
Rajanarayana Kandagatla
Keyword(s):  
Sustained Release ◽  
Release Kinetics ◽  
In Vitro Release ◽  
Methyl Cellulose ◽  
Immediate Release ◽  
Matrix Tablets ◽  
Metformin Hydrochloride ◽  
Matrix Tablet ◽  
Metformin Hcl

 The aim of present study was to design the concept of bilayered tablets containing Glimepride for immediate release using sodium starch glycolate as super disintegrant and Metformin hydrochloride (HCl) for sustained release by using  Hydroxyl propyl methyl cellulose (HPMC K 4M) and Sodium Carboxy Methyl cellulose (SCMC) as the matrix forming polymer, and PVPK-30 as binder. The tablets were evaluated for physicochemical properties. All the values were found to be satisfactory. In vitro release studies were carried out as per USP in pH 1.2 with (0.1% sodium lauryl sulphate w/v) and phosphate buffer pH 6.8 using the apparatus I. The release kinetics of Metformin HCl was evaluated using the regression coefficient analysis. The formulated tablets (F5) shows zero order release and diffusion was the dominant mechanism of drug release. The polymer (HPMC K4M, SCMC) and binder PVPK-30 had significant effect on the release of Metformin HCl matrix tablets (F5). Thus formulated bilayer tablets provided immediate release of Glimepride and Metformin HCl as sustained release over a period of 8 hours.  Stability studies and FT-IR studies clearly indicated that there is no drug –polymer interaction.

Sign in / Sign up

Export Citation Format

Share Document